Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
New initiation of renal replacement therapy – at longest available · people with AHF
Ultrafiltration (UF) showed no clear difference in new initiation of renal replacement therapy – at longest available compared with usual care (UC) (low certainty).
1 finding from 1 review
Neonatal jaundice requiring phototherapy · fetal malposition in labour
1 finding from 1 review
Neonatal jaundice requiring phototherapy · fetal malposition in labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular morbidity Combined endpoint: necessity of reinstating antihypertensive therapy and severe cardiovascular complications · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Intervention not reported
Duration of continuous positive airway pressure therapy (hours or days) · preterm infants less than 30 weeks' gestational age requiring conventional mechanical ventilation for respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
Duration of oxygen therapy (hours) · late preterm and full‐term infants with transient tachypnea of the newborn
1 finding from 1 review
Duration of oxygen therapy (hours) · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Intervention not reported
Sclerotherapy(1 RCT, 85 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(1 RCT, 85 participants) (very low certainty).
1 finding from 1 review
OR 0.55 [0, 272.05]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(No direct RCT) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(No direct RCT) (very low certainty).
1 finding from 1 review
OR 1.19 [0.02, 80.24]
Studies not reported
Very low